The reduced level of PTEN has been associated with enhanced cancer sensitivity to mTOR inhibitors and could be a potential target for CRISPR/Cas9-mediated gene editing in BC [65, 66].Patients with defective BRCA1/2 genes have poor DNA repair capacity and are more susceptible to developing BC [67]. This evidence concerns the gene PTEN and breast cancer.